Literature DB >> 10464316

Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2.

T Renné1, J Dedio, J C Meijers, D Chung, W Müller-Esterl.   

Abstract

Plasma prekallikrein, a zymogen of the contact phase system, circulates in plasma as heterodimeric complex with H-kininogen. The binding is mediated by the prekallikrein heavy chain consisting of four apple domains, A1 to A4, to which H-kininogen binds with high specificity and affinity (K(D) = 1.2 x 10(-8) M). Previous work had demonstrated that a discontinuous kininogen-binding site is formed by a proximal part located in A1, a distal part exposed by A4, and other yet unidentified portion(s) of the kallikrein heavy chain. To detect relevant binding segment(s) we recombinantly expressed single apple domains and found a rank order of binding affinity for kininogen of A2 > A4 approximately A1 > A3. Removal of single apple domains in prekallikrein deletion mutants reduced kininogen binding by 21 (A1), 64 (A2), and 24% (A4), respectively, whereas deletion of A3 was without effect. Transposition of homologous A2 domain from prekallikrein to factor XI conferred high-affinity kininogen binding from the former to the latter. The principal role of A2 for H-kininogen docking to the prekallikrein heavy chain was further substantiated by the finding that cleavage of a single peptide bond in A2 drastically diminished the H-kininogen binding affinity. Furthermore, the epitope of monoclonal antibody PKH6 which blocks kallikrein-kininogen complex formation with an IC(50) of 8 nM mapped to the center portion of domain A2. Our data indicate that domain A2 and two flanking sequence segments of A1 and A4 form a discontinuous binding platform for H-kininogen on the prekallikrein heavy chain. Domain-specific antibodies directed to these critical sites efficiently interfered with contact phase-induced bradykinin release from H-kininogen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464316     DOI: 10.1074/jbc.274.36.25777

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Differential VASP phosphorylation controls remodeling of the actin cytoskeleton.

Authors:  Peter M Benz; Constanze Blume; Stefanie Seifert; Sabine Wilhelm; Jens Waschke; Kai Schuh; Frank Gertler; Thomas Münzel; Thomas Renné
Journal:  J Cell Sci       Date:  2009-10-13       Impact factor: 5.285

Review 2.  In vivo roles of factor XII.

Authors:  Thomas Renné; Alvin H Schmaier; Katrin F Nickel; Margareta Blombäck; Coen Maas
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

3.  Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP.

Authors:  Tatiana F Ottaiano; Sheila S Andrade; Cleide de Oliveira; Mariana C C Silva; Marcus V Buri; Maria A Juliano; Manoel J B C Girão; Misako U Sampaio; Alvin H Schmaier; Alexander Wlodawer; Francisco H A Maffei; Maria Luiza V Oliva
Journal:  Biochimie       Date:  2017-01-20       Impact factor: 4.079

4.  Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III.

Authors:  Jenny Björkqvist; Steven de Maat; Urs Lewandrowski; Antonio Di Gennaro; Chris Oschatz; Kai Schönig; Markus M Nöthen; Christian Drouet; Hal Braley; Marc W Nolte; Albert Sickmann; Con Panousis; Coen Maas; Thomas Renné
Journal:  J Clin Invest       Date:  2015-07-20       Impact factor: 14.808

5.  Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.

Authors:  Brian S Hamilton; Gary R Whittaker
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

Review 6.  Role of plasma kallikrein in diabetes and metabolism.

Authors:  E P Feener; Q Zhou; W Fickweiler
Journal:  Thromb Haemost       Date:  2013-05-16       Impact factor: 5.249

Review 7.  The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities.

Authors:  Marie Worm; Elodie C Köhler; Rachita Panda; Andy Long; Lynn M Butler; Evi X Stavrou; Katrin F Nickel; Tobias A Fuchs; Thomas Renné
Journal:  Ann Transl Med       Date:  2015-10

8.  Biological network inferences for a protection mechanism against familial Creutzfeldt-Jakob disease with E200K pathogenic mutation.

Authors:  Sol Moe Lee; Myungguen Chung; Kyu Jam Hwang; Young Ran Ju; Jae Wook Hyeon; Jun-Sun Park; Chi-Kyeong Kim; Sangho Choi; Jeongmin Lee; Su Yeon Kim
Journal:  BMC Med Genomics       Date:  2014-08-22       Impact factor: 3.063

Review 9.  Modulation of the Plasma Kallikrein-Kinin System Proteins Performed by Heparan Sulfate Proteoglycans.

Authors:  Guacyara Motta; Ivarne L S Tersariol
Journal:  Front Physiol       Date:  2017-07-11       Impact factor: 4.566

Review 10.  Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis.

Authors:  Lysann Bender; Henri Weidmann; Stefan Rose-John; Thomas Renné; Andy T Long
Journal:  Front Immunol       Date:  2017-09-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.